| Similar Articles |
|---|
 |
The Motley Fool
January 17, 2008
Brian Orelli |
EPIX's Epic Oops The EPIX clinical trial data on their Alzheimer's medication wasn't as positive as it first appeared.   |
The Motley Fool
June 14, 2007
Ryan Fuhrmann |
Dueling Fools: GlaxoSmithKline Bear Rebuttal There are better opportunities to use short-term pain and establish positions in pharmaceuticals with better long-term potential. |
The Motley Fool
January 14, 2005
W.D. Crotty |
An FDA OK That Hurts EPIX Pharmaceuticals gets a qualified "yes" from the FDA, sending its stock tumbling. |
The Motley Fool
December 20, 2007
Brian Orelli |
What Was That Clinical Trial For? EPIX Pharmaceuticals initiates a phase 2A study of its Alzheimer's disease drug, PRX-03140, to get safety and tolerability information. Instead, it got good efficacy data. |
BusinessWeek
March 6, 2006
Gene G. Marcial |
Why Glaxo Looks More Robust Big pharma, besieged by generic rivals, is hardly a Street favorite. But GlaxoSmithKline may be an exception. |
The Motley Fool
October 27, 2005
Stephen D. Simpson |
A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock. |
The Motley Fool
February 8, 2006
Stephen D. Simpson |
Glaxo: Healthy Drugmaker Glaxo combines a huge sales force, a rich pipeline, and solid returns on capital. This company should get a thorough look from anyone putting new money into the pharma space. |
The Motley Fool
December 17, 2008
Brian Orelli |
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. |
The Motley Fool
February 8, 2008
Brian Lawler |
Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper. |
The Motley Fool
May 1, 2008
Brian Lawler |
Glaxo's Global Growth Gambit The pharmaceutical's new CEO has changes in mind. |
The Motley Fool
February 14, 2005
Stephen D. Simpson |
Glaxo Stays Above the Fray The British drugmaker looks to regain momentum this year. Investors who are comfortable with the general industry risks and are looking for a relatively "clean" pharmaceutical company should do some research on Glaxo shares. |
The Motley Fool
December 1, 2005
Brian Gorman |
Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note. |
The Motley Fool
February 5, 2009
Brian Orelli |
Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink With sales dropping, more cuts were inevitable. |
The Motley Fool
August 24, 2010
Matthew Brown |
Netflix's Epix Mistake Land grabs don't work in commodity-based businesses. |
The Motley Fool
October 23, 2008
Brian Orelli |
Glaxo to Competitors: You're Cheaper Than We Are This big pharma has cash and it plans to use it. |
The Motley Fool
October 28, 2004
Bill Mann |
Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year. |
Home Theater
August 11, 2010
Mark Fleischmann |
Netflix Approaches Pay-TV Window Netflix has signed an unusual agreement that will let it stream titles from three major studios three months after cable and satellite providers get them. |
The Motley Fool
February 3, 2011
Owain Bennallack |
Glaxo Sweetens a Bitter Pill The drugmaker reports a loss, but resumes share buybacks. |
The Motley Fool
November 9, 2006
Brian Lawler |
The Best Blue Chip for 2007: GlaxoSmithKline Here's a blue-chip pharma stock for your portfolio. |
The Motley Fool
July 25, 2008
Brian Lawler |
Glaxo Changes Course Will a shift in strategy turn the drugmaker around? |
The Motley Fool
July 26, 2006
Stephen D. Simpson |
GlaxoSmithKline: Reliable, Dependable ... Kinda Boring This is a good-but-not-great pharmaceutical giant with a good-but-not-great valuation. Investors, take note. |
The Motley Fool
April 28, 2008
Brian Lawler |
Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers. |
The Motley Fool
December 19, 2006
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Nuvelo... Hubbell... EPIX Pharmaceuticals... Spartech... Companhia de Saneamento Basico do Estado de Sao Paulo... etc. |
